// App-Quantinova.ai

5076 : Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.

Researchers

Presenter

  • Larissa Mendes

Principal Investigators

  • Emily Grist

  • Adnan Ali

  • Sara Santos Vidal

  • Marina Parry

  • Sharanpreet Lall

  • Nafisah B. Atako

  • Sofeya Ishaq

  • Malissa Richmond

  • Aine Haran

  • Alex Hoyle

  • Leila Zakka

  • Christopher Sweeney

  • Noel W. Clarke

  • Mahesh K. B. Parmar

  • Nicholas D. James

  • Louise C. Brown

  • Daniel Berney

  • Gerhardt Attard

Medical Centers

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Kings College London, London, United Kingdom

  • University of Manchester, Manchester, United Kingdom

  • Queen Mary University of London, London, United Kingdom

  • MRC Clinical Trials Unit, UCL, London, United Kingdom

  • The Christie and Salford Royal Hospitals, Manchester, United Kingdom

  • The Christie NHS Foundation Trust (retired), Manchester, United Kingdom

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

  • GenitoUrinary Cancer Research Group, The Christie and Salford Royal Hospitals, Manchester, United Kingdom

  • Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom

  • Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom

  • MRC Clinical Trials Unit, UCL, London, United Kingdom

  • Bart's Cancer Institute, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

  • Proliferation marker protein Ki-67

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • NCT00268476

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved